Factors impeding the discovery of an intervention-based treatment for type 1 diabetes

Expression of Human Leukocyte Antigen Class I in Endocrine and Exocrine Pancreatic Tissue at Onset of Type 1 Diabetes

(2015) Oskar Skog et al.   AMERICAN JOURNAL OF PATHOLOGY

The Streetlight Effect in Type 1 Diabetes

(2015) Manuela Battaglia et al.   DIABETES

Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro

(2015) Lars Krogvold et al.   DIABETES

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?

(2015) Adrian M. Di Bisceglie et al.   HEPATOLOGY

Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes

(2014) Teresa Rodriguez-Calvo et al.   DIABETES

Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes

(2014) Sefina Arif et al.   DIABETES

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

(2014) Michael J. Haller et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune therapy for treating type 1 diabetes: challenging existing paradigms

(2014) Jay S. Skyler   JOURNAL OF CLINICAL INVESTIGATION

Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial

(2013) J. M. Lachin et al.   DIABETES

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings

(2013) Alberto Pugliese et al.   PEDIATRIC DIABETES

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

(2013) Mark R Rigby et al.   Lancet Diabetes & Endocrinology

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

(2011) Jean-François Bach   LANCET

Insulitis in human type 1 diabetes

(2011) Peter In't Veld   Islets

Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes

(2010) G. S. Eisenbarth   DIABETES

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Combination therapies for Type 1 diabetes: why not now?

(2010) Matthias von Herrath   Immunotherapy

Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients

(2010) Jason L. Gaglia et al.   JOURNAL OF CLINICAL INVESTIGATION

Update on Worldwide Efforts to Prevent Type 1 Diabetes

(2009) Jay S. Skyler et al.   Annals of the New York Academy of Sciences

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE